| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Lumacaftor/ivacaftor |
| Brand | Orkambi® |
| Indication | For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. |
| Assessment Process | |
| Rapid review commissioned | 26/11/2015 |
| Rapid review completed | 15/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 11/03/2016 |
| NCPE assessment completed | 01/06/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
“The manufacturer Vertex Pharmaceuticals have confirmed that patients currently receiving Orkambi under the Managed Access Scheme will continue to receive the drug until reimbursement is finalised in Ireland”
